ArticleFrontiers in pharmacology2022

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data.

Quanfeng Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.